Pharmacology Flashcards

1
Q

Effects of Glucocorticosteroids

A

Anti-inflammatory
Bind & block promoter sites of proinflammatorty genes IL-1 alpha & IL-2 beta
Decreased production of TNF alpha
Multiple cell specific effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Proinflammatory Mediators Glucocorticosteroids Inhibits

A
Phospholipase A2
Cyclooxygenase 2
Nitric oxide synthetase
Prostaglandins
Leukotrienes
Thromboxanes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Effect of Glucocorticosteroids on Leukocytes

A

Can’t exit circulation as readily

Entry to site of infection & tissues injury impaired

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Glucocorticosteroids & Suppression of Inflammatory Response

A

Increased neutrophils
Decreased eosinophils
Decreased monocytes
Decrease lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glucocorticosteroids & Effects of Acquired Immunity

A

Decreased APCs
Decreased T cells
Decreased B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Increased Infection Risk with Glucocorticosteroids

A

Immediate reduction of phagocytic responses

Main infections on long term therapy: herpes zoster, staph, candida

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Monitoring for Toxicity of Glucocorticosteroids

A
BP
Serum glucose
Lipid profile
Eye exam
Bone density
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pros of Steroids

A

No dose adjustment in renal impairment

Good symptom relief of pain secondary to inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Short Term Symptom Management for RA

A

NSAIDs

Steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

NSAIDs & RA

A

May alleviate the symptoms

Do not prevent irreversible joint damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glucocorticoids & RA

A

Quick symptoms relief
Avoid long term administration due to toxicities
Not a profound effect on decreasing joint destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DMARDs & RA

A

Variable response
Discontinuation rate high
Continued indefinitely unless significant toxicity
Biological & non-biological

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Non-Biological DMARDs

A
Methotrexate
Sulfasalazine
Hydroxychloroquine
Leflunomide
D-penicillamine
Gold salt
Azithroprine
Cyclosporine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Biological DMARDs

A
Etanercept (Enbrel)
Adilimumab (Humira)
Infliximab (Remicade)
Aakinra (Kineret)
Abatacept (Orencia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

2nd Line if Failure to Achieve RA Remission in 3 Months

A

Change DMARD

Go to combination therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How to decide on which drug for RA?

A

Disease severity
Prognostic factors
Patient preference

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Methotrexate (Rheumatrex)

A

DMARD of choice for RA

Generally well tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

MOA of Methotrexate (Rheumatrex)

A

Stimulates adenosine release
Reduced neutrophil adhesion
Suppression of cell mediated immunity
Anti proliferative effect on synovial fibroblasts & endothelial
Inhibition of IL-1, IL-6, & IL-8
Inhibits synovial collegenase gene suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What do all patients on methotrexate need?

A

Folic acid supplemet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Contraindications of Methotrexate (Rheumatrex)

A

Women contemplating pregnancy
Pregnancy
Liver disease or excessive ETOH intake
GFR less than 30 mL/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

SE of Methotrexate (Rheumatrex)

A
Hepatotoxicity
Pulmonary toxicity
Myelosuppression
Nephrotoxicity
Fatigue
Decreased ability to concentrate
Alopecia
Nausea
Stomach upset
Loos stools
Soreness of the mouth
Rash on the extremities
Headache
Fever
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Toxicities of Methotrexate (Rheumatrex)

A

Myelosuppression
Hepatotoxicity including cirrhosis
Pulmonary toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Monitoring of Methotrexate (Rheumatrex)

A
CBC
LFTs
Albumin
Creatinine
Pre treatment CXR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

2nd Line Drug for RA

A

Sulfasalazine (Azulfidine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

MOA of Sulfasalazine (Azulfidine)

A

Inhibition of PMN cell migration
Reduced lymphocyte responses
Inhibits angiogenesis
Decreases inflammatory cytokines & IgM RF production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Contraindications of Sulfasalazine (Azulfidine)

A
Sulfa allergy
Pregnancy category D
GI or GU tract obstruction
Porphyria
Platelet count less than 50K
LFTs > 2x ULN
Hepatitis
Men wanting to conceive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

SE of Sulfasalazine (Azulfidine)

A
Nausea & diarrhea
Intestinal or urinary obstruction
Oral ulcers
Orange-yellow pigmentation of the skin
Headache
Depression
Neutropenia
Thrombocytopenia
Agranulocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Toxicity of Sulfasalazine (Azulfidine)

A

Myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Monitoring of Sulfasalazine (Azulfidine)

A

CBC monthly x3

CBC every 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Effects Leflunomide (Avara)

A

Anti-inflammatory
Antiproliferative
Decreases progression of joint erosions & joint space narrowing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

MOA of Leflunomide (Avara)

A

Competitive inhibitor of dihydrofolate reductase
Decreases production of pyrimidine
Inhibits pyrimidine synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Contraindications to Leflunomide (Avara)

A

Pregnancy
Preexisting liver disease
Alcoholism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

SE of Leflunomide (Avara)

A
Diarrhea
Rash
Reversible alopecia
Hepatotoxicity
Weight loss
HTN
Bone marrow suppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Leflunomide (Avara) Toxicities

A

Hepatotoxicity

Bone marrow suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Monitoring of Leflunomide (Avara)

A

Monthly x 6 then every 2 months
CBC
Liver enzymes
Creatinine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Interactions with Leflunomide (Avara)

A

Weak inhibitor of CYP2C9
Increase warfarin levels
Rifampin may increase levels of leflunomide
Bile acid sequesterants decrease effectiveness of leflunomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Hydroxychloroquine (Plaquenil) & RA

A

Antimalarial

Does not limit progression of RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Use of Hydroxychloroquine (Plaquenil)

A

Mild RA with no evidence of joint destruction & no inflammatory markers or autoimmune markers
Add-on to methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

MOA of Hydroxychloroquine (Plaquenil)

A

Interferes with normal antigen processing
Inhibits lysosomal enzymes & IL-1 release
Inhibition of PMNs & lymphocyte responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Toxicity of Hydroxychloroquine (Plaquenil)

A

Macular damage

41
Q

Monitoring with Hydroxychloroquine (Plaquenil)

A

Fundoscopic & visual field exams every 6-12 months

42
Q

SE of Hydroxychloroquine (Plaquenil)

A
Nausea
Diarrhea
Abdominal discomfort
Photosnsitivity
Skin pigmentation changes
Rash
Macular damage
43
Q

Drug Interactions with Hydroxychloroquine (Plaquenil)

A

Decreased metabolism of beta blockers

May increase cyclosporine & digoxin levels

44
Q

Treatment of Severe RA

A

Combination of DMARD therapy
Switch to another TNF inhibitor with different mechanism
Ongoing glucocorticoid therapy
Ongoing NSAIDs

45
Q

TNF Inhibitors

A

Etanercept (Enbrel)
Infliximab (Remicade)
Adalimumab (Humira)

46
Q

MOA of TNF Inhibitors

A

Bind to TNF-alpha, cell lysis occurs

Interferes with inflammatory activity

47
Q

SE of TNF Inhibitors

A
Injection site infections
Infusion reaction (infliximab-Remicade)
Serious infections leading to sepsis
Do not administer live vaccine
Response to other vaccines may be diminished
48
Q

Contraindications of TNF Inhibitors

A

Latent TB infection

High risk for opportunistic infections

49
Q

Interactions of Infliximab (Remicade)

A

Abatacept (Orencia)
Anakinra (Kineret)
Increased risk of infection

50
Q

Methotrexate & Infliximab (Remicade)

A

Decreases development of infliximab antibodies

51
Q

Toxicity of TNF Inhibitors

A

Injection site reaction

Increased risk of local or systemic infection

52
Q

Monitoring of TNF Inhibitors

A

PPD prior to therapy

Periodic CBC

53
Q

MOA of Anakinra (Kineret)

A

Blocks IL-1 receptor to decrease degree of joint destruction & inflammation

54
Q

Anakinra (Kineret) & GFR less than 30 mL/min

A

Decrease dose

55
Q

Contraindications of Anakinra (Kineret)

A

Sensitivity to E. coli-derived proteins
Preexisting infection or high risk for infection
Not to be used in combination with TNF inhibitors

56
Q

SE of Anakinra (Kineret)

A

Skin irruption at injection site
Infection
Possible angioedema & anaphylaxis
Decrease in WBCs

57
Q

Monitoring in Anakinra (kineret) Use

A

CBC monthly x3

CBC Q4 months x 1 year

58
Q

Non-preferred DMARDS

A

D-penicillamine
Azithroprine
Cyclosporine A
Gold compounds

59
Q

D-Penicillamine

A

Chelating agent for metal poisoning, arsenic poisoning, or Wilson’s disease
Depresses T cell activity
Pregnancy category D

60
Q

Aithroprine (Imuran)

A

Inhibits enzymatic activity required for DNA synthesis
Adjust dose for decreased renal clearance
Pregnancy category D
Major toxicity = bone marrow suppression
Carcinogenic

61
Q

Cyclosporine A

A

Blocks activation of T cells & IL-2
Follow blood levels
Many drug interactions
Toxicity: renal failure

62
Q

Gold Compounds

A

Decreases prostaglandin production
Add-on therapy
Greater toxicity than DMARDs

63
Q

Medications that May Lead to a SLE Exacerbation

A

Sulfa containing antibiotics
Minocycline
OCPs

64
Q

Medication that May Lead to Drug Induced Lupus

A

Procainamide
Hydralazine
Griseofulvin

65
Q

Medications that Work for Cutaneous & Musculoskeletal Involvement of SLE

A

Anti-malarials

Hydroxychloroqine (Plaquenil)

66
Q

Medications for Cutaneous Involvement of SLE

A

Topical therapies

67
Q

Medication for Musculoskeletal Involvement of SLE

A

NSAIDs

68
Q

Medications for Significant Organ Involvement in SLE

A

Glucocorticoids

69
Q

Immune Modulators for Severe SLE When Steroid Resistent

A
Methotrexate
Cyclophosphamide
Azathiprine
Mycophenolate
Rituximab
70
Q

Medication When Antiphospholipid Antibody Positive in SLE

A

Warfarin

71
Q

Medications to Treat Acute Attacks of Gout

A

NSAIDs
Colchicine
Steroids

72
Q

Medications for Prevention of Gout

A
Xanthine oxidase inhibitors: allopurinol (Zyloprim), febuxostat
Uricosuric drugs (Probenecid)
73
Q

MOA of NSAIDs

A

Inhibit cyclooxygenase & production of mediators of inflammation

74
Q

Contraindications of NSAIDs

A
CrCl less than 60 mL/min
Active duodenal or gastric ulcers
HF
Uncontrolled HTN
Allergy
Chronic anticoagulation
75
Q

NSAIDs Increase Risk of

A
CVA
MI
CHF
A-fib
CV death
76
Q

Aspirin & NSAIDs

A

Take aspirin 2 hours prior to NSAIDs

77
Q

NSAIDs Acute Gout

A

Indomethacin (Indocin)
Naproxen
Celecoxib (Celebrex)

78
Q

Colchicine for Acute Gout Attacks

A

NSAID intolerance

NSAID contraindication

79
Q

MOA of Colchicine

A

Prevents activation degranulation & migration of neutrophils associated with mediating some gout symptoms

80
Q

Pregnancy Category of Colchicine

A

Category C

81
Q

SE of Colchicine

A
Diarrhea
N/V
Reversible peripheral neuropathy
Bone marrow suppression
Myopathy
82
Q

Dose Adjustment Needed in Colchicine

A
>70 years old
CrCl less than 30 mL/min
Avoid in dialysis patients
Strong CYP3A4 inhibitors
Moderate CYP3A4 inhibitors
P-glycoprotein inhibitors
83
Q

Examples of Strong CYP 3A4 Inhibitors

A
Clarithromycin
Itraconozaole
Ketoconazole
Nefazodone
HIV protease inhibitors
84
Q

Examples of Moderate CYP3A4 Inhibitors

A
Diltiazem
Erythromycin
Fluconazole
Grape fruit juice
Verapamil
85
Q

Examples of P-Glycoprotein Inhibitors

A

Cyclosporine
Ranolazine
Amiodarone

86
Q

Contraindications to Colchicine

A

Renal impairment

Hepatic impairment

87
Q

No Relief of Symptoms on Colchicine After 24 Hours

A

+ glucocorticoid

Cautiously in conjunction with an NSAID

88
Q

Management Between Gout Attacks

A

Avoid thiazides & loop diuretics
Avoid niacin
Avoid aspirin

89
Q

Medications to Reduce Serum Uric Acid Indications

A

2+ episodes a year
Tophi
CKD Stage II+

90
Q

Allopurinol (Zyloprim)

A

Agent of choice for lowering rate
Xanthine oxidase inhibitor
Goal level: less than 6

91
Q

MOA of Allopurinol (Zyloprim)

A

Inhibits xanthine oxidase needed for eventual conversion of hypoxanthine to uric acid

92
Q

Necessary Dose Adjustment in Allopurinol (Zyloprim)

A

Renal Failure: less than 60 mL/min

93
Q

SE of Allopurinol (Zyloprim)

A
Skin rash
Gout attack
Diarrhea
Nausea
Elevated liver enzymes
Hypersensitivity reactions
Bone marrow suppression
Hepatotoxicity
94
Q

2nd Line Therapy for Prevention of Gout

A

Probenecid

95
Q

MOA of Probenecid

A

Blocks tubular reabsorption of filtered rate & increases uric acid excretion by the kidney

96
Q

When is probenecid not effective?

A

CrCl less than 50 mL/min

97
Q

Contraindications of Probenecid

A

Hx of nephrolithiasis

98
Q

Prevention of Uric Acid Stones with Use of Probenecid

A

Increase fluid intake

Need agent to alkalinize the urine

99
Q

Other Medications that can Decrease Uric Acid Levels

A

Losartan
Fenofibrate
Vitamin C 500mg daily
Cherries